icad (ICAD) Risk Assessment

View and export this data going back to 1992. Start your Free Trial

What is icad Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of icad is: High Risk: High uncertainty.

Competitive Comparison of icad's Risk Assessment

For the Medical Devices subindustry, icad's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

icad's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, icad's Risk Assessment distribution charts can be found below:

* The bar in red indicates where icad's Risk Assessment falls into.

icad (NAS:ICAD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

icad Risk Assessment Related Terms

Thank you for viewing the detailed overview of icad's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062

Website

https://www.icadmed.com

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Executives

Eric Lonnqvist	officer: See Remarks	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea	officer: See Remarks	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go	officer: Sr. VP of R&D	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno	officer: See Remarks	C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine	director	82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton	director	C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood	director	845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein	director	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter	officer: See Remarks	C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens	officer: Executive VP of Marketing	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado	officer: Interim Chief FinancialOfficer	98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel	director	15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard	director	C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831